<DOC>
	<DOC>NCT00038948</DOC>
	<brief_summary>The purpose of this study is to determine the effect of conversion from calcineurin inhibitor to sirolimus based therapy on renal function.</brief_summary>
	<brief_title>Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Age greater than or equal to 13 years. Receiving CsA or tacrolimus from the time of transplantation or within 2 weeks thereafter Patients with a functioning allograft and a Nankivell GFR greater than or equal to 20 mL/min, within 2 weeks before randomization Biopsyconfirmed acute rejection within 12 weeks before randomization, that was determined to require antirejection treatment Patients in whom kidneypancreas or other multiple organ transplants have been performed</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Renal</keyword>
	<keyword>Allograft</keyword>
	<keyword>Recipients</keyword>
</DOC>